Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2004 4
2005 3
2006 5
2007 8
2008 11
2009 8
2010 4
2011 7
2012 11
2013 11
2014 15
2015 11
2016 9
2017 11
2018 6
2019 10
2020 10
2021 17
2022 16
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Results by year

Filters applied: . Clear all
Page 1
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.
Reeves DB, Mayer BT, deCamp AC, Huang Y, Zhang B, Carpp LN, Magaret CA, Juraska M, Gilbert PB, Montefiori DC, Bar KJ, Cardozo-Ojeda EF, Schiffer JT, Rossenkhan R, Edlefsen P, Morris L, Mkhize NN, Williamson C, Mullins JI, Seaton KE, Tomaras GD, Andrew P, Mgodi N, Ledgerwood JE, Cohen MS, Corey L, Naidoo L, Orrell C, Goepfert PA, Casapia M, Sobieszczyk ME, Karuna ST, Edupuganti S. Reeves DB, et al. Among authors: williamson c. Nat Commun. 2024 Mar 22;15(1):2575. doi: 10.1038/s41467-024-46805-8. Nat Commun. 2024. PMID: 38519455 Free PMC article. No abstract available.
The timing of HIV-1 infection of cells that persist on therapy is not strongly influenced by replication competency or cellular tropism of the provirus.
Joseph SB, Abrahams MR, Moeser M, Tyers L, Archin NM, Council OD, Sondgeroth A, Spielvogel E, Emery A, Zhou S, Doolabh D, Ismail SD, Karim SA, Margolis DM, Pond SK, Garrett N, Swanstrom R, Williamson C. Joseph SB, et al. Among authors: williamson c. PLoS Pathog. 2024 Feb 29;20(2):e1011974. doi: 10.1371/journal.ppat.1011974. eCollection 2024 Feb. PLoS Pathog. 2024. PMID: 38422171 Free PMC article.
Two-step evolution of HIV-1 budding system leading to pandemic in the human population.
Konno Y, Uriu K, Chikata T, Takada T, Kurita JI, Ueda MT, Islam S, Yang Tan BJ, Ito J, Aso H, Kumata R, Williamson C, Iwami S, Takiguchi M, Nishimura Y, Morita E, Satou Y, Nakagawa S, Koyanagi Y, Sato K. Konno Y, et al. Among authors: williamson c. Cell Rep. 2024 Feb 27;43(2):113697. doi: 10.1016/j.celrep.2024.113697. Epub 2024 Jan 30. Cell Rep. 2024. PMID: 38294901 Free article.
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features.
Juraska M, Bai H, deCamp AC, Magaret CA, Li L, Gillespie K, Carpp LN, Giorgi EE, Ludwig J, Molitor C, Hudson A, Williamson BD, Espy N, Simpkins B, Rudnicki E, Shao D, Rossenkhan R, Edlefsen PT, Westfall DH, Deng W, Chen L, Zhao H, Bhattacharya T, Pankow A, Murrell B, Yssel A, Matten D, York T, Beaume N, Gwashu-Nyangiwe A, Ndabambi N, Thebus R, Karuna ST, Morris L, Montefiori DC, Hural JA, Cohen MS, Corey L, Rolland M, Gilbert PB, Williamson C, Mullins JI. Juraska M, et al. Among authors: williamson c. Proc Natl Acad Sci U S A. 2024 Jan 23;121(4):e2308942121. doi: 10.1073/pnas.2308942121. Epub 2024 Jan 19. Proc Natl Acad Sci U S A. 2024. PMID: 38241441
SARS-CoV-2 Viral Replication Persists in the Human Lung for Several Weeks after Symptom Onset.
Tomasicchio M, Jaumdally S, Wilson L, Kotze A, Semple L, Meier S, Pooran A, Esmail A, Pillay K, Roberts R, Kriel R, Meldau R, Oelofse S, Mandviwala C, Burns J, Londt R, Davids M, van der Merwe C, Roomaney A, Kühn L, Perumal T, Scott AJ, Hale MJ, Baillie V, Mahtab S, Williamson C, Joseph R, Sigal A, Joubert I, Piercy J, Thomson D, Fredericks DL, Miller MGA, Nunes MC, Madhi SA, Dheda K. Tomasicchio M, et al. Among authors: williamson c. Am J Respir Crit Care Med. 2024 Apr 1;209(7):840-851. doi: 10.1164/rccm.202308-1438OC. Am J Respir Crit Care Med. 2024. PMID: 38226855 Free PMC article.
Changing character and waning impact of COVID-19 at a tertiary centre in Cape Town, South Africa.
Hermans LE, Booysen P, Boloko L, Adriaanse M, de Wet TJ, Lifson AR, Wadee N, Papavarnavas N, Marais G, Hsiao NY, Rosslee MJ, Symons G, Calligaro GL, Iranzadeh A, Wilkinson RJ, Ntusi NAB, Williamson C, Davies MA, Meintjes G, Wasserman S. Hermans LE, et al. Among authors: williamson c. S Afr J Infect Dis. 2023 Dec 18;38(1):550. doi: 10.4102/sajid.v38i1.550. eCollection 2023. S Afr J Infect Dis. 2023. PMID: 38223432 Free PMC article.
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.
Reeves DB, Mayer BT, deCamp AC, Huang Y, Zhang B, Carpp LN, Magaret CA, Juraska M, Gilbert PB, Montefiori DC, Bar KJ, Cardozo-Ojeda EF, Schiffer JT, Rossenkhan R, Edlefsen P, Morris L, Mkhize NN, Williamson C, Mullins JI, Seaton KE, Tomaras GD, Andrew P, Mgodi N, Ledgerwood JE, Cohen MS, Corey L, Naidoo L, Orrell C, Goepfert PA, Casapia M, Sobieszczyk ME, Karuna ST, Edupuganti S. Reeves DB, et al. Among authors: williamson c. Nat Commun. 2023 Dec 14;14(1):8299. doi: 10.1038/s41467-023-43384-y. Nat Commun. 2023. PMID: 38097552 Free PMC article.
Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial.
Mahomed S, Garrett N, Potloane D, Sikazwe IT, Capparelli E, Harkoo I, Gengiah TN, Zuma NY, Osman F, Mansoor L, Archary D, Myeni N, Radebe P, Samsunder N, Doria-Rose N, Carlton K, Gama L, Koup RA, Narpala S, Serebryannyy L, Moore P, Williamson C, Pozzetto B, Hankins C, Morris L, Karim QA, Abdool Karim S. Mahomed S, et al. Among authors: williamson c. BMJ Open. 2023 Aug 28;13(8):e076843. doi: 10.1136/bmjopen-2023-076843. BMJ Open. 2023. PMID: 37640457 Free PMC article.
179 results